The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
BACKGROUND
To identify the prevalence and clinical outcomes of pT0 disease following neoadjuvant hormonal therapy (NHT) and radical prostatectomy (RP) in high-risk prostate cancer.


METHODS
We retrospectively included 111 patients who had received NHT and RP for the treatment of high-risk prostate cancer. We classified the patients into two groups, the pT0 group and the non-pT0 group, depending on whether a residual tumor was observed.


RESULTS
We identified 6 cases (5.4%) with pT0 disease after reviewing the slides of all patients. There was no recurrence of disease in the pT0 group during a median follow-up of 59 months. Among the 105 patients in the non-pT0 group, biochemical recurrence (BCR) developed in 60 patients (57.1%), with the median time to BCR being 14 months.


CONCLUSIONS
Among the 111 patients with high-risk prostate cancer, we found 6 cases that showed a complete pathological response after NHT and no recurrence of disease during the follow-up, meaning that the androgen deprivation therapy could potentially eradicate high-risk prostate cancer. This is one of the largest studies demonstrating the prevalence of pT0 disease and its outcomes after NHT among patients with high-risk prostate cancer.
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea. urojy@ncc.re.kr.
Jae Young
JY
Joung
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea. kje0917@ncc.re.kr.
Jeong Eun
JE
Kim
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea. 12112@ncc.re.kr.
Sung Han
SH
Kim
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea. seohk@ncc.re.kr.
Ho Kyung
HK
Seo
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea. cjs5225@ncc.re.kr.
Jinsoo
J
Chung
Department of Pathology, National Cancer Center, Goyang, South Korea. thymus@ncc.re.kr.
Weon Seo
WS
Park
Department of Pathology, National Cancer Center, Goyang, South Korea. hongek@ncc.re.kr.
Eun Kyung
EK
Hong
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea. uroonoc@ncc.re.kr.
Kang Hyun
KH
Lee
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015897:Comorbidity; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000401:mortality; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000517:prevention & control*; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D015995:Prevalence; D011468:Prostatectomy / Q000401:mortality*; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D056910:Republic of Korea / Q000453:epidemiology; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
D000726:Androgen Antagonists